GMED
VENTE TOTALE: 25 000 titres (~2 175 965,00 $ US)
- Insiders
- ZARRILLI STEPHEN T
- Total bought
- —
- Total sold
- $2,175,965
- Last activity
- 2026-08-18
- Last synced
-
2026-08-25 17:08:49
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-21
GMED exhibits exceptional financial health — strong liquidity (90), improving fundamentals (85), minimal debt, and solid margin expansion in 2025 — providing a robust structural foundation.
The first sentence of the analysis written for GMED on 2026-08-21 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 67.4% | 58.9% | 65.1% | 74.2% | 75.0% | |
| Ebit Margin | 20.8% | 8.7% | 12.9% | 23.1% | 20.3% | |
| Ebitda Margin | 24.8% | 18.8% | 22.1% | 29.8% | 27.6% | |
| Operating Profit Margin | 16.3% | 6.6% | 8.5% | 22.3% | 17.9% | |
| Pretax Profit Margin | 20.8% | 4.8% | 10.5% | 23.8% | 18.8% | |
| Continuous Operations Profit Margin | 18.3% | 4.1% | 7.8% | 18.6% | 15.6% | |
| Net Profit Margin | 18.3% | 4.1% | 7.8% | 18.6% | 15.6% | |
| Bottom Line Profit Margin | 18.3% | 4.1% | 7.8% | 18.6% | 15.6% | |
| Current Ratio | 4.264 | 2.544 | 4.882 | 6.177 | 6.168 | |
| Quick Ratio | 2.741 | 1.774 | 2.720 | 4.299 | 4.477 | |
| Solvency Ratio | 0.902 | 0.332 | 0.246 | 1.125 | 1.015 | |
| Cash Ratio | 1.055 | 0.916 | 1.191 | 0.945 | 1.377 | |
| Price To Earnings Ratio | 21.937 | 108.829 | 48.890 | 39.296 | 48.784 | |
| Price To Earnings Growth Ratio | 0.052 | -3.595 | -1.155 | 1.419 | 1.153 | |
| Forward Price To Earnings Growth Ratio | 0.052 | -3.595 | -1.155 | 1.419 | 1.153 | |
| Price To Earnings Diluted Ratio | 22.273 | 110.280 | 49.804 | 40.146 | 50.139 | |
| Price To Earnings Diluted Growth Ratio | 0.053 | -3.687 | -1.181 | 1.410 | 1.178 | |
| Price To Book Ratio | 2.580 | 2.687 | 1.507 | 4.041 | 4.177 | |
| Price To Sales Ratio | 4.015 | 4.456 | 3.842 | 7.295 | 7.591 | |
| Price To Free Cash Flow Ratio | 20.042 | 27.704 | 36.474 | 71.459 | 33.153 | |
| Price To Operating Cash Flow Ratio | 15.661 | 21.562 | 24.749 | 41.810 | 26.325 | |
| Debt To Assets Ratio | 0.022 | 0.102 | 0.102 | 0.003 | 0.000 | |
| Debt To Equity Ratio | 0.026 | 0.129 | 0.130 | 0.003 | 0.000 | |
| Debt To Capital Ratio | 0.025 | 0.114 | 0.115 | 0.003 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.022 | 0.000 | 0.095 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.160 | 1.257 | 1.272 | 1.124 | 1.124 | |
| Working Capital Turnover Ratio | 1.994 | 1.771 | 1.336 | 1.321 | 1.344 | |
| Operating Cash Flow Ratio | 1.511 | 0.608 | 0.621 | 1.121 | 1.971 | |
| Operating Cash Flow Sales Ratio | 0.256 | 0.207 | 0.155 | 0.174 | 0.288 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.781 | 0.778 | 0.679 | 0.585 | 0.794 | |
| Debt Service Coverage Ratio | 0.000 | 1.019 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 39.625 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 1.174 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 6.350 | 0.969 | 0.468 | 29.690 | 0.000 | |
| Capital Expenditure Coverage Ratio | 4.575 | 4.510 | 3.111 | 2.410 | 4.856 | |
| Dividend Paid And Capex Coverage Ratio | 4.575 | 4.510 | 3.111 | 2.410 | 4.856 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 15.608 | 23.175 | 17.541 | 24.031 | 26.744 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 67.4% | ▲8.5% | ▼-0.7% |
| Ebit Margin | 20.8% | ▲12.0% | ▲3.6% |
| Ebitda Margin | 24.8% | ▲6.0% | ▲0.2% |
| Operating Profit Margin | 16.3% | ▲9.7% | ▲2.0% |
| Pretax Profit Margin | 20.8% | ▲16.0% | ▲5.0% |
| Continuous Operations Profit Margin | 18.3% | ▲14.2% | ▲5.4% |
| Net Profit Margin | 18.3% | ▲14.2% | ▲5.4% |
| Bottom Line Profit Margin | 18.3% | ▲14.2% | ▲5.4% |
| Current Ratio | 4.264 | ▲1.720 | ▼-0.543 |
| Quick Ratio | 2.741 | ▲0.967 | ▼-0.461 |
| Solvency Ratio | 0.902 | ▲0.570 | ▲0.178 |
| Cash Ratio | 1.056 | ▲0.139 | ▼-0.042 |
| Price To Earnings Ratio | 21.937 | ▼-86.892 | ▼-31.610 |
| Price To Earnings Growth Ratio | 0.052 | ▲3.646 | ▲0.477 |
| Forward Price To Earnings Growth Ratio | 0.052 | ▲3.646 | ▲0.477 |
| Price To Earnings Diluted Ratio | 22.273 | ▼-88.007 | ▼-32.255 |
| Price To Earnings Diluted Growth Ratio | 0.053 | ▲3.740 | ▲0.498 |
| Price To Book Ratio | 2.580 | ▼-0.107 | ▼-0.418 |
| Price To Sales Ratio | 4.015 | ▼-0.441 | ▼-1.425 |
| Price To Free Cash Flow Ratio | 20.042 | ▼-7.662 | ▼-17.724 |
| Price To Operating Cash Flow Ratio | 15.661 | ▼-5.900 | ▼-10.360 |
| Debt To Assets Ratio | 0.022 | ▼-0.080 | ▼-0.024 |
| Debt To Equity Ratio | 0.026 | ▼-0.103 | ▼-0.032 |
| Debt To Capital Ratio | 0.025 | ▼-0.089 | ▼-0.026 |
| Long Term Debt To Capital Ratio | 0.022 | ▲0.022 | ▼-0.001 |
| Financial Leverage Ratio | 1.159 | ▼-0.098 | ▼-0.028 |
| Working Capital Turnover Ratio | 1.994 | ▲0.222 | ▲0.440 |
| Operating Cash Flow Ratio | 1.511 | ▲0.903 | ▲0.345 |
| Operating Cash Flow Sales Ratio | 0.256 | ▲0.050 | ▲0.040 |
| Free Cash Flow Operating Cash Flow Ratio | 0.781 | ▲0.003 | ▲0.058 |
| Debt Service Coverage Ratio | 0.000 | ▼-1.019 | ▼-0.204 |
| Interest Coverage Ratio | 0.000 | ▼-39.625 | ▼-7.925 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▼-1.174 | ▼-0.235 |
| Operating Cash Flow Coverage Ratio | 6.350 | ▲5.381 | ▼-1.146 |
| Capital Expenditure Coverage Ratio | 4.575 | ▲0.065 | ▲0.683 |
| Dividend Paid And Capex Coverage Ratio | 4.575 | ▲0.065 | ▲0.683 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 15.608 | ▼-7.567 | ▼-5.812 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $11.80B | $11.23B | $6.03B | $7.46B | $7.27B | |
| Enterprise value | $11.39B | $10.98B | $6.08B | $7.32B | $7.08B | |
| EV / Sales | 3.88x | 4.36x | 3.88x | 7.15x | 7.39x | |
| EV / Op. cash flow | 15.12x | 21.09x | 24.97x | 41.00x | 25.63x | |
| EV / Free cash flow | 19.35x | 27.09x | 36.80x | 70.08x | 32.27x | |
| EV / EBITDA | 15.61x | 23.18x | 17.54x | 24.03x | 26.74x | |
| Net debt / EBITDA | -0.56x | -0.52x | 0.15x | -0.47x | -0.73x | |
| Current ratio | 4.26x | 2.54x | 4.88x | 6.18x | 6.17x | |
| Income quality | 1.40x | 5.06x | 1.98x | 0.94x | 1.85x | |
| Graham number | $55 | $23 | $29 | $28 | $24 | |
| Graham net-net | $6 | $4 | $2 | $5 | $5 | |
| Tax burden | 88.2% | 85.3% | 74.3% | 78.3% | 82.7% | |
| Interest burden | 100.0% | 54.9% | 81.9% | 102.9% | 92.6% | |
| Working capital | $1.63B | $1.32B | $1.52B | $824.1M | $724.4M | |
| Invested capital | $4.44B | $4.16B | $4.53B | $1.33B | $1.19B | |
| Return on assets | 10.1% | 2.0% | 2.4% | 9.2% | 7.6% | |
| Operating ROA | 9.1% | 3.2% | 3.7% | 11.3% | 9.5% | |
| Return on tangible assets | 17.2% | 3.4% | 4.5% | 10.5% | 8.7% | |
| Return on equity | 11.8% | 2.5% | 3.1% | 10.3% | 8.6% | |
| Return on invested capital | 8.8% | 2.9% | 2.1% | 9.3% | 7.8% | |
| Return on capital employed | 10.0% | 3.8% | 2.8% | 11.9% | 9.5% | |
| Earnings yield | 4.6% | 0.9% | 2.0% | 2.5% | 2.1% | |
| Free cash flow yield | 5.0% | 3.6% | 2.7% | 1.4% | 3.0% | |
| Capex / Op. cash flow | 21.9% | 22.2% | 32.1% | 41.5% | 20.6% | |
| Capex / Depreciation | 59.5% | 45.4% | 54.1% | 108.5% | 81.4% | |
| Capex / Sales | 5.6% | 4.6% | 5.0% | 7.2% | 5.9% | |
| SG&A / Sales | 44.8% | 38.9% | 41.0% | 42.2% | 42.6% | |
| R&D / Sales | 6.3% | 6.5% | 7.9% | 7.1% | 10.2% | |
| Stock comp / Sales | 1.7% | 2.2% | 3.4% | 3.2% | 3.2% | |
| Intangibles / Total assets | 41.1% | 42.4% | 46.4% | 12.6% | 12.7% | |
| Days sales outstanding | 92d | 84d | 117d | 78d | 63d | |
| Days payables outstanding | 38d | 26d | 38d | 50d | 33d | |
| Operating cycle | 382d | 316d | 682d | 491d | 425d | |
| Cash conversion cycle | 344d | 290d | 644d | 441d | 391d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+5.1%EV / Sales ▼-11.0%EV / EBITDA ▼-32.7%EV / Op. cash flow ▼-5.966Earnings yield ▲+0.036Graham number ▲+32.125
Profitability
Return on equity ▲+0.093Return on assets ▲+0.082Return on invested capital ▲+0.059Return on capital employed ▲+0.062Operating ROA ▲+0.059Income quality ▼-3.655Tax burden ▲+0.029
Efficiency
Days sales outstanding ▲+8.573Days payables outstanding ▲+11.192Operating cycle ▲+65.544Cash conversion cycle ▲+54.352Capex / Sales ▲+0.010R&D / Sales ▼-0.002
Balance-sheet strength
Current ratio ▲+1.720Net debt / EBITDA ▼-0.036Working capital ▲+305765000.000Invested capital ▲+275040000.000Intangibles / Total assets ▼-0.013
Change over 5 years
Valuation
Market cap ▲+62.2%EV / Sales ▼-47.5%EV / EBITDA ▼-41.6%EV / Op. cash flow ▼-10.506Earnings yield ▲+0.025Graham number ▲+31.046
Profitability
Return on equity ▲+0.032Return on assets ▲+0.025Return on invested capital ▲+0.010Return on capital employed ▲+0.005Operating ROA ▼-0.004Income quality ▼-0.451Tax burden ▲+0.055
Efficiency
Days sales outstanding ▲+29.254Days payables outstanding ▲+4.172Operating cycle ▼-43.010Cash conversion cycle ▼-47.182Capex / Sales ▼-0.003R&D / Sales ▼-0.039
Balance-sheet strength
Current ratio ▼-1.904Net debt / EBITDA ▲+0.171Working capital ▲+902760000.000Invested capital ▲+3241651000.000Intangibles / Total assets ▲+0.284
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-07-10 | Lisa McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-06-24 | Lisa McClain | Sale (Partial) | $1,001 - $15,000 |
| 2025-06-17 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2025-04-09 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-04-03 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2023-03-06 | Daniel Goldman | Sale (Full) | $15,001 - $50,000 |
| 2023-02-08 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-01-11 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2022-08-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-06-27 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2022-05-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2020-06-01 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-05-28 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-03-31 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-02-21 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
Recent news
- 2026-08-20 4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026 PEG-driven GARP picks EnerSys, Globus Medical, DoubleVerify and Match Group pair discounted valuations with strong growth potential.
- 2026-08-19 Globus Medical: 7 Quarters Of Margin Expansion, Priced For None Globus Medical is rated a buy, targeting a 17.5% return over four quarters with a constant 10.56x EV/EBITDA multiple. GMED''s base business is compounding faster than headline growth, with international sales rising 18% and gross margin expanding by 200bps, excluding accounting effects. SG&A leverage drove operating margin improvement, while integration of Nevro remains a known, sized, and management-dated drag.
- 2026-08-17 Here is Why Growth Investors Should Buy Globus Medical (GMED) Now Globus Medical (GMED) is well positioned to outperform the market, as it exhibits above-average growth in financials.
- 2026-08-11 Globus Medical (GMED) Upgraded to Strong Buy: Here''s Why Globus Medical (GMED) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company''s earnings prospects. This might drive the stock higher in the near term.
- 2026-08-11 GMED vs. ITGR: Which Stock Is the Better Value Option? Investors interested in Medical - Instruments stocks are likely familiar with Globus Medical (GMED) and Integer (ITGR). But which of these two stocks is more attractive to value investors?
- 2026-08-08 Globus Medical Q2 Earnings Call Highlights Globus Medical NYSE: GMED reported second-quarter 2026 revenue of $789.6 million, up 6% from a year earlier, as growth in its spine and trauma businesses helped offset declines in enabling technologies and Nevro sales. The company reaffirmed its full-year revenue outlook while raising its adjusted earnings forecast, citing margin expansion and operating leverage in the first half.
- 2026-08-07 GMED Q2 Earnings Call Highlights Margin Gains and Revenue Caution Globus Medical raises 2026 EPS guidance after Q2 margin gains and spine growth while holding sales guidance steady amid Nevro and Enabling Technologies risks.
- 2026-08-06 Globus Medical (GMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Globus Medical (GMED) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
- 2026-08-06 Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript Globus Medical, Inc. (GMED) Q2 2026 Earnings Call Transcript
- 2026-08-06 Globus Medical Reports Second Quarter 2026 Results AUDUBON, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the second quarter ended June 30, 2026.